Among these patients with sHR positive/HER2 negative tumours and an intermediate risk of recurrence who did not receive adjuvant chemotherapy, a high uPA/PAI-1 status (n = 77) was associated with a tenfold higher risk of recurrence compared with patients who had a low uPA/PAI-1 status (n = 120; HR 10.10, 95% CI 1.215–83.947) (Fig. 3), corresponding to absolute risks of recurrence of 10.0% and 0.9%, respectively (Fig. 2C, Supplementary Table S5). Here, ERBB2 is linked to neoplasm.